KRISTIN MARIE ELO
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant LA MESA, CA NPI 1164664306
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant CA NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$4,927.33
- Category: General Payments
- Program years: PY2021–2024
- Record count: 188
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,313.23 across 54 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,213.53 | 53 |
| Long term medical supply or device loan | $99.70 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $239.43 | 8 |
| Celgene Corporation | $180.27 | 8 |
| Merck Sharp & Dohme Corporation | $139.08 | 6 |
| ABBVIE INC. | $67.71 | 3 |
| SpringWorks Therapeutics, Inc. | $53.68 | 2 |
| Regeneron Healthcare Solutions, Inc. | $53.67 | 2 |
| PFIZER INC. | $52.54 | 2 |
| Incyte Corporation | $49.32 | 2 |
| EISAI INC. | $47.36 | 2 |
| E.R. Squibb & Sons, L.L.C. | $33.71 | 2 |
| Lilly USA, LLC | $33.55 | 2 |
| ADC Therapeutics America, Inc. | $32.38 | 1 |
| Deciphera Pharmaceuticals Inc. | $32.20 | 1 |
| Genmab U.S., Inc. | $29.55 | 1 |
| Exelixis Inc. | $26.61 | 1 |
| TerSera Therapeutics LLC | $26.61 | 1 |
| Coherus Biosciences Inc. | $25.93 | 1 |
| Genentech USA, Inc. | $25.87 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.04 | 1 |
| GENZYME CORPORATION | $24.82 | 1 |
| Daiichi Sankyo Inc. | $21.43 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $19.75 | 1 |
| Fennec Pharmaceuticals, Inc. | $19.70 | 1 |
| Adaptive Biotechnologies Corporation | $19.52 | 1 |
| TAIHO ONCOLOGY, INC. | $19.19 | 1 |
| Alnylam Pharmaceuticals Inc. | $14.31 | 1 |
By program year
Records — PY2024 (54)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.